Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with resp
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... ChanTest, the leading expert in ion channels and ... development, and safety -- is one of eight organizations ... and Commercialization Program. Governor Ted Strickland and Interim Director ... the Ohio Third Frontier Commission, Mark Barbash, announced the ...
... Aegera Therapeutics is pleased to announce the initiation ... AEG33773, a novel, orally bio-available small molecule therapeutic ... , The Phase 2a study, entitled A Multicenter, ... Efficacy of AEG33773 versus Placebo in Patients with ...
... May 6 iZumi Bio, Inc., a biotechnology ... stem cell (iPS) technology with the mission of ... differentiation of patient cells, today announced the appointments ... (CTO) and Dushyant Pathak, Ph.D., as vice president ...
Cached Biology Technology:ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... Australian National University (ANU), have developed a new ... variability over the past 5.3 million years., The ... surrounding ice ages over the past two million ... carbon dioxide levels, global temperatures and sea levels., ... (UoS) and the National Oceanography Centre (NOC) in ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... in marine mammals, brains reveals that these animals are ... DDTs and PCBs, as well as emerging contaminants such ... lead author on the study currently in press and ... performed the research as a student in the Woods ...
... radio landscape has made it tough for Foghat to get ... to new research published in The American Naturalist . ... that the songs of white-crowned sparrows change over time in ... factors that drive the evolution of mating signals in birds. ...
... Institutes of Health is launching the first integrated, ... rare and neglected diseases. The $24 million program ... Rare and Neglected Diseases Program, or TRND. ... is unusual because TRND creates a drug development ...
Cached Biology News:Skip this cocktail party 2Skip this cocktail party 3Bird songs change with environment 2NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
... cultured in DMEM with 4 mM L-glutamine medium ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Biology Products: